2.7.1.74: deoxycytidine kinase
This is an abbreviated version!
For detailed information about deoxycytidine kinase, go to the full flat file.
Word Map on EC 2.7.1.74
-
2.7.1.74
-
leukemia
-
gemcitabine
-
thymidine
-
triphosphate
-
deaminase
-
purine
-
ribonucleotide
-
deoxynucleoside
-
pyrimidine
-
deoxyguanosine
-
salvage
-
myeloid
-
arabinoside
-
cytarabine
-
prodrugs
-
deoxyadenosine
-
1-beta-d-arabinofuranosylcytosine
-
deoxyribonucleoside
-
5'-nucleotidase
-
cladribine
-
cross-resistance
-
ara-ctp
-
2-chlorodeoxyadenosine
-
2',2'-difluorodeoxycytidine
-
fludarabine
-
dttp
-
antileukemic
-
ccrf-cem
-
dfdctp
-
2-chloro-2'-deoxyadenosine
-
gemcitabine-resistant
-
dado
-
deoxycytidylate
-
kinase-deficient
-
clofarabine
-
2',3'-dideoxycytidine
-
5'-phosphorylation
-
arabinosyl
-
deoxypyrimidine
-
t-lymphoblastoid
-
deoxycoformycin
-
medicine
-
2'-deoxyadenosine
-
deoxythymidine
-
l-nucleoside
-
dideoxycytidine
-
t-lymphoblasts
-
2',3'-dideoxyinosine
-
tetrahydrouridine
-
arabinosylcytosine
-
anabolites
-
pharmacology
-
analysis
- 2.7.1.74
- leukemia
- gemcitabine
- thymidine
- triphosphate
- deaminase
- purine
- ribonucleotide
- deoxynucleoside
- pyrimidine
- deoxyguanosine
-
salvage
- myeloid
- arabinoside
- cytarabine
-
prodrugs
- deoxyadenosine
- 1-beta-d-arabinofuranosylcytosine
- deoxyribonucleoside
- 5'-nucleotidase
- cladribine
-
cross-resistance
- ara-ctp
- 2-chlorodeoxyadenosine
- 2',2'-difluorodeoxycytidine
- fludarabine
- dttp
-
antileukemic
-
ccrf-cem
-
dfdctp
- 2-chloro-2'-deoxyadenosine
-
gemcitabine-resistant
-
dado
- deoxycytidylate
-
kinase-deficient
- clofarabine
- 2',3'-dideoxycytidine
-
5'-phosphorylation
-
arabinosyl
-
deoxypyrimidine
-
t-lymphoblastoid
- deoxycoformycin
- medicine
- 2'-deoxyadenosine
- deoxythymidine
-
l-nucleoside
- dideoxycytidine
- t-lymphoblasts
- 2',3'-dideoxyinosine
- tetrahydrouridine
- arabinosylcytosine
-
anabolites
- pharmacology
- analysis
Reaction
Synonyms
2'-deoxycytidine kinase, ara-C kinase, arabinofuranosylcytosine kinase, dC kinase, dCK, deoxycytidine kinase, deoxycytidine-cytidine kinase, dNTP:deoxycytidine 5'-phosphotransferase, kinase, deoxycytidine (phosphorylating), NTP:deoxycytidine 5'-phosphotransferase
ECTree
2.7.1.74 deoxycytidine kinaseAdvanced search results
results (
results (Substrates Products
Substrates Products on EC 2.7.1.74 - deoxycytidine kinase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
SUBSTRATE 
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
2',2'-difluoro-2'-deoxyguanosine + ATP
ADP + 2',2'-difluoro-2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
2'-fluoro-2'-deoxyarabinosylcytidine + ATP
ADP + 2'-fluoro-2'-deoxyarabinosylcytidine 5'-phosphate
-
-
-
-
?
2'-fluoro-2'-deoxycytidine + ATP
ADP + 2'-fluoro-2'-deoxycytidine 5'-phosphate
-
-
-
-
?
3'-O-methyl-2'-deoxycytidine + ATP
ADP + 3'-O-methyl-2'-deoxycytidine 5'-phosphate
-
-
-
-
?
4'-thio-2'-deoxycytidine + UTP
UDP + 4'-thio-2'-deoxycytidine 5'-phosphate
-
-
-
-
?
4'-thio-beta-D-arabinofuranosylcytosine + UTP
UDP + 4'-thio-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
-
?
9-(beta-D-arabinofuranosyl)-adenine + ATP
9-(beta-D-arabinofuranosyl)-adenine 5'-phosphate + ADP
-
-
-
-
?
9-beta-D-arabinofuranosylguanine + NTP
NDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
ATP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
ADP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + ?
substrate of enzyme mutant R104M/D133A, poor substrate of the wild-type enzyme
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine 5'-phosphate
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine monophosphate
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine monophosphate
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine monophosphate
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine monophosphate
ATP + 1-(2-deoxy-beta-D-ribofuranosyl)-isocarbostyril
ADP + ?
-
poor substrate, 1.4% of the activity with 2'-deoxycytidine
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
?
ATP + 2',2'-difluoro-2'-deoxycytidine
ADP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
-
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-monophosphate
i.e. gemcitabine
-
-
?
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine
-
-
?
ATP + 2'-deoxy-3'-thiacytidine
ADP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
ATP + 2,5-difluoro-4-[1-(2-deoxy-beta-L-ribofuranosyl)]-aniline
ADP + ?
-
nucleoside mimic, 14.6% of the activity with 2'-deoxycytidine
-
-
?
ATP + 5-(3-pyridyl)-2'-deoxycytidine
ADP + 5-(3-pyridyl)-2'-deoxycytidine 5'-phosphate
-
cytosolic enzyme, poor substrate
-
-
?
ATP + 5-(4-pyridyl)-2'-deoxycytidine
ADP + 5-(4-pyridyl)-2'-deoxycytidine 5'-phosphate
-
cytosolic enzyme, poor substrate
-
-
?
ATP + beta-L-2',3'-dideoxy-3'-thiacytidine
ADP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
ATP + difluoro-arabinofuranosyl adenine
ADP + difluoro-arabinofuranosyl adenine 5'-phosphate
i.e. fludarabine
-
-
?
ATP + difluorodeoxycytidine
ADP + difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine
-
-
?
ATP + L-2',3'-dideoxy-3'-thiacytidine
ADP + L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
-
?
ATP + L-thymidine
?
human dCK, in addition to being able to phosphorylate both purines and pyrimidines, has the special ability to accept L-nucleosides as substrates
-
-
?
beta-D-3'-hydroxymethyl-2',3'dideoxycytidine + ATP
ADP + beta-D-3'-hydroxymethyl-2',3'dideoxycytidine 5'-phosphate
-
-
-
-
?
dCTP + 2'-deoxycytidine
dCDP + 2'-deoxy-CMP
-
only in the absence of ATP
-
-
?
GTP + deoxycytidine
GDP + dCMP
-
optimal activity with GTP as phosphoryl donor
-
-
?
NTP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
NDP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
activation of the clinically relevant substrate
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
NTP + 1-beta-D-arabinosylcytosine
NDP + 1-beta-D-arabinosylcytosine 5'-phosphate
i.e. cytaribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
NDP + 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine 5'-phosphate
i.e. clofarabine, rate-limiting step in the activation of the prodrug, precursor of an effective chemotherapeutic agent for leukemias and other haematological malignancies
-
-
?
NTP + 9-beta-D-arabinofuranosyl-2-fluoroadenine
NDP + 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate
-
-
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
NTP + 9-beta-D-arabinosyl-2-fluoroadenine
NDP + 9-beta-D-arabinosyl-2-fluoroadenine 5'-phosphate
-
phosphorylation of chemotherapeutically important nucleoside analogues
-
-
?
NTP + deoxythymidine
NDP + dTMP
-
mitochondrial isozyme, better than deoxycytidine, not cytosolic isozyme I
-
-
?
NTP + troxacitabine
?
activation of the clinically relevant substrate
-
-
?
UTP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
UDP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
UTP + 1-beta-D-arabinofuranosylcytosine
UDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
i.e. cytarabine
-
-
?
UTP + 2',2'-difluorodeoxycytidine
UDP + 2',2'-difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine
-
-
?
UTP + 2-chloro-2'-deoxyadenosine
UDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
UTP + 2-chlorodeoxyadenosine
UDP + 2-chlorodeoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
UTP + 2-fluoro-9-beta-D-arabinofuranosyladenine
UDP + 2-fluoro-9-beta-D-arabinofuranosyladenine 5'-phosphate
i.e. fludarabine
-
-
?
UTP + 9-beta-D-arabinofuranosylguanine
UDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
i.e. nelarabine
-
-
?
UTP + beta-L-2',3'-dideoxy-3'-thiacytidine
UDP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
UTP + beta-L-dioxolane-cytidine
UDP + beta-L-dioxolane-cytidine 5'-phosphate
antitumor drug
-
-
?
UTP + difluoro-arabinofuranosyl adenine
UDP + difluoro-arabinofuranosyl adenine 5'-phosphate
i.e. fludarabine
-
-
?
UTP + difluorodeoxycytidine
UDP + difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine
-
-
?
UTP + L-2',3'-dideoxy-3'-thiacytidine
UDP + L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
-
?
9-beta-D-arabinofuranosylguanine + NTP
NDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
-
-
-
-
?
9-beta-D-arabinofuranosylguanine + NTP
NDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
-
-
-
-
?
ATP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
ADP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
ATP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
ADP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
i.e. lamivudine
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine monophosphate
-
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
-
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
-
-
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine monophosphate
-
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine monophosphate
-
i.e. gemcitabine, transport and metabolism in vivo, overview
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
660812, 661034, 661040, 661330, 662521, 662988, 662989, 662992, 671801, 671908, 671911, 694483, 703020, 703425, 704730, 704900, 706027
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
involved in nucleotide synthesis, involved in DNA repair
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
in the presence of DTT less effective than dUTP, UTP, dTTP or GTP, without DTT only less effective than dUTP
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
best phosphate donor cytosolic isozyme II and mitochondrial isozyme
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
i.e. cladribine
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
-
i.e. cladribine
-
-
?
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
ATP + arabinosyl cytosine
ADP + arabinosyl cytosine 5'-phosphate
-
i.e. cytosar
-
-
?
ATP + arabinosyl cytosine
ADP + arabinosyl cytosine 5'-phosphate
i.e. cytosar
-
-
?
ATP + cytarabine
ADP + cytarabine 5'-phosphate
-
drug against acute myeloid and lymphoblastic leukemia
-
-
?
ATP + cytarabine
ADP + cytarabine 5'-phosphate
-
i.e. 1-beta-D-arabinofuranosylcytosine
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + ?
-
key anabolic enzyme for activation of purine or pyrimidine deoxynucleosides as well as cytidine arabinoside and other anti-tumor drugs
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
-
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
i.e. difluorodeoxycytidine
-
-
?
CTP + 2'-deoxycytidine
CDP + 2'-deoxy-CMP
-
as good as GTP, UTP, dATP, mitochondrial isozyme
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
poor substrate of mitochondrial isozyme
-
-
?
dUTP + 2'-deoxycytidine
dUDP + 2'-deoxy-CMP
-
best phosphate donor, cytosolic enzyme I, poor, mitochondrial isozyme
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
as good as dGTP, dTTP or dUTP, cytosolic isozyme I
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
as good as CTP, dATP or UTP, mitochondrial isozyme
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
antineoplastic agent
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
i.e. cytarabine, rate limiting enzyme in the activation of the prodrug
-
-
?
NTP + 2',2'-difluoro-2'-deoxycytidine
NDP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
-
best acceptor substrate, best phosphate donors: UTP or NTP-mixture, better than ATP
-
-
?
NTP + 2',2'-difluoro-2'-deoxycytidine
NDP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
-
cytosolic isozyme I, not mitochondrial isozyme
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of solid malignant tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine, rate limiting enzyme in the activation of the pharmaceutically relevant substrate which is commonly used in the treatment of solid malignant tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine, rate limiting enzyme in the activation of the pharmaceutically relevant substrate which is commonly used in the treatment of tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
substrate also termed gemcitabine
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
antiviral agent
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine, activation of the pharmaceutically relevant substrate which is used in the treatment of HIV infections
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
-
poor
-
-
?
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
antiviral agent
-
-
?
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
i.e. lamivudine, activation of the pharmaceutically relevant substrate which is used in the treatment of HIV infections
-
-
?
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
more effective substrate than 2'-deoxyadenosine and 2'-deoxyguanosine
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
i.e. cladribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine, antineoplastic agent
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
phosphorylation of chemotherapeutically important nucleoside analogues
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
-
activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
i.e. fludarabine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
ATP can be replaced by GTP, dATP, dGTP or dTTP
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
i.e. 1-beta-arabinofuranosyl cytosine, L-isomer better substrate than D-isomer
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
-
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
D-isomer
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
best phosphate donors: UTP or NTP-mixture, even better than ATP
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
cytosolic isozyme I
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
no acceptor substrate for cytosolic isozyme II or mitochondrial isozyme
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
enzyme shows little specificity towards phosphate donor
-
?
NTP + deoxycytidine
NDP + dCMP
-
in order of decreasing activity: dGTP, CTP, ATP, dATP, dTTP, UTP, GTP
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: beta-gamma-methylene diphosphonate analogue of dTTP
-
?
NTP + deoxycytidine
NDP + dCMP
-
beta-D-2'-deoxyribonucleosides are more efficient than corresponding beta-D-arabinonucleosides or beta-ribonucleosides, rather nonspecific for base moiety of nucleoside substrate
-
?
NTP + deoxycytidine
NDP + dCMP
-
best acceptor substrate at low substrate concentrations
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
641939, 641940, 641943, 641945, 641947, 641948, 641953, 641963, 641965, 641967, 641970, 722221, 738175, 739431
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
enzyme shows little specificity towards phosphate donor
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: uridine arabinoside, cytosine
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: nucleoside diphosphates and their deoxy derivatives
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
enzyme shows little specificity towards phosphate donor
-
?
NTP + deoxyguanosine
NDP + dGMP
-
-
-
-
?
NTP + deoxyuridine
NDP + dUMP
-
mitochondrial isozyme, not cytosolic isozyme I
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
-
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
-
i.e. zalcitabine, activation of the pharmaceutically relevant substrate which is used for the treatment of HIV infections
-
-
?
UTP + 2'-deoxy-3'-thiacytidine
UDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
UTP + 2'-deoxy-3'-thiacytidine
UDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
i.e. lamivudine, activation of the pharmaceutically relevant substrate which is used for the treatment of HIV infections
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
as good as CTP, GTP or dATP
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
best phosphate donor at low substrate levels
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
preferred donor and acceptor substrates
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + arabinosyl cytosine
UDP + arabinosyl cytosine 5'-phosphate
-
i.e. cytosar
-
-
?
UTP + arabinosyl cytosine
UDP + arabinosyl cytosine 5'-phosphate
i.e. cytosar
-
-
?
additional information
?
-
-
purine deoxynucleoside activity inseparably associated with deoxycytidine kinase protein
-
-
?
additional information
?
-
-
multisubstrate enzyme, that also phosphorylates purine deoxyribonucleotides
-
-
?
additional information
?
-
-
remarkably relaxed enantioselectivity with respect to cytidine derivatives in beta configuration
-
-
?
additional information
?
-
-
several isozymes: cytosolic deoxycytidine kinase I and II, plus mitochondrial isozyme
-
-
?
additional information
?
-
-
lack of enantioselectivity for D- and L-analogues of cytidine and adenosine
-
-
?
additional information
?
-
-
presumably one common nucleoside acceptor site
-
-
?
additional information
?
-
-
enzyme exists in different conformational states with different substrate kinetic properties
-
-
?
additional information
?
-
-
reacts with both enantiomers of beta-deoxycytidine, beta-deoxyguanidine, beta-deoxyadenosine, and alpha-D-deoxycytidine is also substrate
-
-
?
additional information
?
-
-
reacts with both enantiomers of beta-deoxyadenosine, beta-arabinofuranosyl-adenine and beta-deoxyguanine
-
-
?
additional information
?
-
-
5'-phosphorylation of is a crucial step in metabolic activation of anticancer and antiviral nucleoside antimetabolites, such as cladribine, gemcitabine, cytarabine, and lamivudine
-
-
?
additional information
?
-
de novo synthesis and salvage of ribonucleotides and deoxyribonucleotides, metabolism overview, enzyme is active and medically important in anticancer and antiviral therapy due to high phosphorylation activity of prodrugs, overview
-
-
?
additional information
?
-
-
enzyme is active and medically important in anticancer and antiviral therapy due to high phosphorylation activity of prodrugs, overview
-
-
?
additional information
?
-
-
resistance of cells to cytarabine is caused by dCK enzyme deficiency
-
-
?
additional information
?
-
-
the activation of the enzyme is a first step in 2-chloro-2'-deoxyadenosine-induced cytotoxicity
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurrence of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
additional information
?
-
-
the enzyme is active and important in activation of several clinically important deoxynucleoside analogues used for the treatment of haematological and solid malignancies
-
-
?
additional information
?
-
-
broad substrate specificity, overview, binding of acceptor subtrates is more tightly in presence of phosphate donor molecules
-
-
?
additional information
?
-
enzyme can utilizes several phosphate donors, with preference for UTP
-
-
?
additional information
?
-
-
no activity with several difluorophenyl nucleoside analogues and with 1-(2-deoxy-beta-D-ribofuranosyl)-7-iodoisocarbostyril, overview
-
-
?
additional information
?
-
substrate-enzyme interactions, overview, enzyme prefers nucleosides with sugars in the S-conformation, i.e C2'-endo-C3'-exo, binding of substrate induces conformational changes, the phosphate donor influences the acceptor substrate specificity, mechanism, overview
-
-
?
additional information
?
-
catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway, key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy
-
-
?
additional information
?
-
-
catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway, key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy
-
-
?
additional information
?
-
-
dCK is able to phosphorylate both D- and L-nucleosides and nucleoside analogs
-
-
?
additional information
?
-
dCK is able to phosphorylate both D- and L-nucleosides and nucleoside analogs
-
-
?
additional information
?
-
-
enzyme of the salvage pathway for deoxyribonucleotide synthesis, which provides resting cells with deoxynucleotides for DNA repair and mitochondrial DNA synthesis, important enzyme for the phosphorylation/activation of deoxynucleoside analogues, which are cytotoxic towards both replicating and indolent malignancies
-
-
?
additional information
?
-
-
essential for the synthesis of deoxynucleotides required for DNA repair and involved in deoxynucleoside analogue activation
-
-
?
additional information
?
-
-
key enzyme in the deoxynucleoside salvage pathway and in the activation of numerous nucleoside analogues used in cancer and antiviral chemotherapy
-
-
?
additional information
?
-
phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue anticancer and antiviral prodrugs
-
-
?
additional information
?
-
-
phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue anticancer and antiviral prodrugs
-
-
?
additional information
?
-
-
dCK phosphorylates all three natural deoxyribonucleosides, exhibiting the highest affinity for 2'-deoxycytidine
-
-
?
additional information
?
-
-
dCK interacts with cyclin-dependent kinase 1 (Cdk1) and the interaction inhibits Cdk1 activity both in vitro and in vivo
-
-
?
additional information
?
-
-
development and evaluation of a homogeneous fluorescence-based assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities, detailed overview
-
-
?
additional information
?
-
-
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil is no substrate. But 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine can be converted to 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil by cytidine deaminase
-
-
?
additional information
?
-
-
deoxycytidine kinase shows broad substrate specificity, catalyzing the phosphorylation of deoxycytidine, deoxyadenosine, and deoxyguanosine with ATP or UTP as phosphoryl donor
-
-
?
additional information
?
-
substrate specificity or wild-type an dmutant enzymes, overview
-
-
?
additional information
?
-
-
substrate specificity or wild-type an dmutant enzymes, overview
-
-
?
additional information
?
-
the human enzyme is not active with the acyclic guanine analogue acyclovir. Acyclovir binds at the dCK active site, but does so adopting a nonproductive conformation. Despite binding ACV, the enzyme remains in the open, inactive state, overview. dCK would phosphorylate acyclic guanine analogs if they can induce a similar rotation
-
-
?
additional information
?
-
-
the human enzyme is not active with the acyclic guanine analogue acyclovir. Acyclovir binds at the dCK active site, but does so adopting a nonproductive conformation. Despite binding ACV, the enzyme remains in the open, inactive state, overview. dCK would phosphorylate acyclic guanine analogs if they can induce a similar rotation
-
-
?
additional information
?
-
the enzyme shows no activity with zidovudine, stavudine, iodoxuridine, thymidine and deoxyuridine
-
-
-
additional information
?
-
-
enzyme has two separate active sites for deoxycytidine and deoxyadenosine activity
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurrence of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
additional information
?
-
-
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil is no substrate. But 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine can be converted to 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil by cytidine deaminase
-
-
?
additional information
?
-
-
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil is no substrate. But 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine can be converted to 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil by cytidine deaminase
-
-
?
